Advice
Following a full submission
buprenorphine/naloxone (Suboxone) is accepted for restricted use within NHS Scotland for substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment.
In the pivotal trial buprenorphine/naloxone was superior to placebo and had similar efficacy and safety to buprenorphine. There are currently no published trials comparing buprenorphine/naloxone with methadone.
Buprenorphine/naloxone is restricted to those patients in whom methadone is not suitable and for whom the use of buprenorphine is considered appropriate.
Download detailed advice44KB (PDF)
Medicine details
- Medicine name:
- buprenorphine/naloxone (Suboxone)
- SMC ID:
- 355/07
- Indication:
- Substitution treatment for opioid drug dependence
- Pharmaceutical company
- Schering-Plough Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 12 March 2007